Get the Stockscreener App
1,014.34
2.10%
20.70
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,014.34, with a volume of 2.58M.
It is up +2.10% in the last 24 hours and up +2.62% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$993.64
Open:
$1008.15
24h Volume:
2.58M
Relative Volume:
0.70
Market Cap:
$907.81B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
50.17
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+0.00%
1M Performance:
+2.62%
6M Performance:
+25.47%
1Y Performance:
+27.45%
1-Day Range:
$987.00
$1,031.56
1-Week Range:
$977.12
$1,031.56
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,014.29 | 889.33B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
210.35 | 497.62B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.44 | 397.98B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
133.22 | 251.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
98.86 | 242.30B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly stock maintains Outperform rating at Bernstein on GLP-1 expansion - Investing.com India
Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide - Proactive financial news
Zepbound Maker Eli Lilly Reports Patients Achieved Dramatic Weight Loss in Study of Newest Obesity Drug - The New York Sun
Eli Lilly soars 31% higher says confident analyst - Rolling Out
Eli Lilly (LLY) Shows Competitive Efficacy in Initial Obesity St - GuruFocus
Lilly’s Experimental Shot Cuts Body Weight by 23% in Study - Bloomberg.com
Lilly reports promising results from its weight-loss drug trial - ConsumerAffairs
Eli Lilly's (LLY) New Weight Loss Drug Shows Promising Results i - GuruFocus
Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain - Benzinga
Eli Lilly's obesity drug trial results, Coca-Cola names next CEO - Yahoo Finance
Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial - The Wall Street Journal
Lilly's next-gen drug tops Zepbound on weight loss in late-stage trial - Reuters
Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug - The New York Times
Eli Lilly delivers positive data from next-generation obesity drug - medwatch.com
Eli Lilly’s New Obesity Treatment Shows Weight Loss Up To 71.2 Lbs, Reduces Pain In Trial - Stocktwits
Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some - Fierce Biotech
Eli Lilly Picks Site for $6B Manufacturing Plant - CommercialSearch
Eli Lilly's (LLY) Retatrutide Shows Promising Results in Weight Loss Trial - GuruFocus
Eli Lilly’s newest weight-loss drug relieved pain in patients with knee osteoarthritis - MarketWatch
Eli Lilly Reports Positive Results From Study of Weight Loss Drug - The Wall Street Journal
Eli Lilly Invests $6 Billion as Active Pharmaceutical Ingredient (API) Production Expands in Huntsville, Alabama - IMARC Group
Eli Lilly (LLY) Reveals Promising Results from TRIUMPH-4 Study o - GuruFocus
Oracle, Adobe and Broadcom fall premarket; Eli Lilly gains - Investing.com
Eli Lilly’s Strategic Advancements in Incretin Pipeline and Diversification Drive Buy Rating - TipRanks
Eli Lilly shot helped patients lose 29% of body weight - Financial Times
Stock Movers: Oracle, Eli Lilly, Gemini - Bloomberg.com
Lilly posts late-stage trial win for next-gen weight loss drug - Seeking Alpha
Eli Lilly's retatrutide delivers weight loss of up to average of 71.2 lbs in phase 3 trial - marketscreener.com
Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations - statnews.com
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - CNBC
MrMed Partners with Eli Lilly to Expand Access to Affordable GLP-1 Medications in India - openPR.com
Local church toy drive gets $30k boost from Eli Lilly and Co., Fluor, contractors to help Boone County Children - reporter.net
Eli Lilly rumored to be interested in acquiring promising French biotech company - medwatch.com
Eli Lilly's Mounjaro Added to China's National Health Insurance for Diabetes - Finviz
Eli Lilly’s Mounjaro added to China’s national health insurance for diabetes - MSN
Eli Lilly to invest $6B in Limestone manufacturing facility - timesdaily.com
Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative? - Yahoo Finance
Locals weigh in on new Eli Lilly plant coming to Huntsville - rocketcitynow.com
Eli Lilly ends in green after nine consecutive sessions of decline - MSN
How Investors May Respond To Eli Lilly (LLY) Doubling Down On Manufacturing And Oncology Beyond Obesity - simplywall.st
UAH, Calhoun weigh in on Eli Lilly plant coming to North Alabama - WHNT.com
Limestone Co. officials weigh in on infrastructure concerns regarding Eli Lilly coming to Huntsville - WAFF
Lilly To Build $6B Pharmaceutical Manufacturing Facility In Alabama - InkFreeNews.com
Eli Lilly (LLY) Rebounds Amid Takeover Speculation and Strategic Expansion - GuruFocus
Warning: This Skyrocketing Stock Has a Hidden Risk - AOL.com
Major pharmaceutical company to build $6B facility creating over 3,000 jobs - MassLive
Lilly - timesdaily.com
Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
Eli Lilly's Weight-Loss Drugs Drove Its Stock Higher This Year. A New Plant in Alabama Could Boost Production - Investopedia
Wells Fargo Raises Price Target for Eli Lilly (LLY) to $1200 wit - GuruFocus
Lilly to Build Third, $6B Manufacturing Plant - Powder & Bulk Solids
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):